- Home
- IDYA vs ATHM Comparison
IDYA vs ATHM Comparison
Compare IDYA & ATHM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IDYA
- ATHM
- Stock Information
- Founded
- IDYA 2015
- ATHM 2008
- Country
- IDYA United States
- ATHM China
- Employees
- IDYA N/A
- ATHM N/A
- Industry
- IDYA Biotechnology: Pharmaceutical Preparations
- ATHM EDP Services
- Sector
- IDYA Health Care
- ATHM Technology
- Exchange
- IDYA Nasdaq
- ATHM Nasdaq
- Market Cap
- IDYA 2.9B
- ATHM 3.3B
- IPO Year
- IDYA 2019
- ATHM 2013
- Fundamental
- Price
- IDYA $34.21
- ATHM $23.54
- Analyst Decision
- IDYA Buy
- ATHM Hold
- Analyst Count
- IDYA 14
- ATHM 1
- Target Price
- IDYA $49.58
- ATHM $28.00
- AVG Volume (30 Days)
- IDYA 992.0K
- ATHM 362.6K
- Earning Date
- IDYA 11-04-2025
- ATHM 11-06-2025
- Dividend Yield
- IDYA N/A
- ATHM 10.22%
- EPS Growth
- IDYA N/A
- ATHM N/A
- EPS
- IDYA N/A
- ATHM 1.73
- Revenue
- IDYA $214,834,000.00
- ATHM $951,436,680.00
- Revenue This Year
- IDYA $90.17
- ATHM N/A
- Revenue Next Year
- IDYA $217.29
- ATHM $1.33
- P/E Ratio
- IDYA N/A
- ATHM $13.59
- Revenue Growth
- IDYA 5377.66
- ATHM N/A
- 52 Week Low
- IDYA $13.45
- ATHM $23.11
- 52 Week High
- IDYA $34.66
- ATHM $32.70
- Technical
- Relative Strength Index (RSI)
- IDYA 68.23
- ATHM 32.04
- Support Level
- IDYA $31.15
- ATHM $23.11
- Resistance Level
- IDYA $34.66
- ATHM $24.17
- Average True Range (ATR)
- IDYA 1.58
- ATHM 0.68
- MACD
- IDYA 0.11
- ATHM -0.05
- Stochastic Oscillator
- IDYA 89.86
- ATHM 14.35
About IDYA IDEAYA Biosciences Inc.
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275/GSK959 (Werner Helicase), IDE161 (PARG), and IDE705/GSK101 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.
About ATHM Autohome Inc.
Founded in 2008 as a media content platform, Autohome is the leading online automobile platform in China, ranking first among automotive service platforms in terms of mobile daily active users, according to QuestMobile. Through its two websites, autohome.com.cn and che168.com, Autohome delivers comprehensive, independent and interactive content and tools to automobile consumers as well as a full suite of services to automakers and dealers. According to iResearch, the company was the largest online automotive advertising and lead generation service provider with 30% market share, in terms of media services and lead generation revenue, in China's online auto platform media advertising market.